Sanofi and Regeneron halted a Phase III study of the checkpoint inhibitor Libtayo (cemiplimab) as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.
Bristol-Myers Squibb and Exelixis are eying potential approval of a combination therapy for renal cell carcinoma following results from a late-stage study that showed a combination of Opdivo and Cabometyx met the primary endpoint of progression-free survival.
A preliminary analysis of late-stage trial data showed that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer (NSCLC).
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.
AstraZeneca reported that high-level data analysis from the company’s Phase III CASPIAN trial demonstrated that Imfinzi (durvalumab) in combination with standard-of-care chemotherapies confirmed a clinically meaningful and sustained overall survival benefit in patients with extensive-stage small cell lung cancer treated in the first-line setting.
Bristol-Myers Squibb’s combination treatment for multiple myeloma failed to hit the endpoint of progression-free survival in a Phase III test.
Medidata, a global leader in creating end-to-end solutions to support the entire clinical trial process and a Dassault Systèmes company, announced that Medpace Inc. entered into an agreement to integrate Medidata Rave Imaging with Medpace’s imaging systems and workflow.
Cambridge, Massachusetts-based Unum Therapeutics announced a restructuring in order to shift assets toward the company’s preclinical program, BOXR1030, for solid tumors.
Shares of Karyopharm Therapeutics soared after the company posted positive Phase III results in multiple myeloma and announced plans for a regulatory submission in the second quarter of 2020 for a combination of Xpovio, Velcade and Dexamethasone.
A federal judge ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved must be made public.